Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial

Breast Cancer Research and Treatment
Isabell WitzelVolkmar Müller

Abstract

In the context of neoadjuvant therapy (NT) for breast cancer patients, different targeted therapy approaches are currently evaluated in clinical trials. Serum markers could help to monitor and optimize such treatment strategies. We investigated human epidermal growth factor receptor 2 serum (sHER2) levels in 175 breast cancer patients participating in the GeparQuattro trial. This study incorporated NT approaches and additional trastuzumab treatment for all patients with HER2-positive tumors. Human epidermal growth factor receptor 2 serum levels were measured by enzyme-linked immunosorbent assay (ELISA) before initiation of NT and after NT (pre-surgery) in a HER2-positive (n = 90) and a HER2-negative patient cohort (n = 85). Median pre-chemotherapy sHER2 levels were higher in patients with positive HER2 status of the primary tumor than in patients with negative HER2 status (14.9 ng/ml vs. 7.7 ng/ml, P < 0.001). A pre-chemotherapy sHER2 cut-off level of 10 ng/ml had the best sensitivity and specificity in discriminating between HER2-positive and HER2-negative primary tumors. In HER2-positive patients, we found a significant positive association between pathological complete remission (pCR) and elevated sHER2 levels (above 15 ng/m...Continue Reading

References

Mar 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Allan LiptonJ Allard
Mar 29, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Francisco J EstevaGabriel N Hortobagyi
Jan 17, 2003·Journal of the National Cancer Institute·Gottfried KonecnyDennis J Slamon
Jun 28, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Manfred KaufmannHans-Jörg Senn
Mar 12, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Wolfgang J KöstlerChristoph C Zielinski
Aug 18, 2005·Journal of the National Cancer Institute·Lisa M McShaneUNKNOWN Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Jun 15, 2006·Breast Cancer Research and Treatment·Daniel F HayesMarc E Lippman
Apr 19, 2007·Journal of the National Cancer Institute·Maurizio ScaltritiJosé Baselga
Sep 6, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W Fraser SymmansLajos Pusztai
May 10, 2008·Surgical Oncology·Mallika TewariHari S Shukla
Dec 2, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Peter S Hall, David A Cameron
Mar 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alexandra F LearyMitch Dowsett
Mar 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Siân LennonBrian Leyland-Jones
Mar 12, 2009·Current Cancer Drug Targets·Philippe L BedardFatima Cardoso
Apr 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael UntchGottfried E Konecny
Mar 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael UntchGunter von Minckwitz
Mar 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gunter von MinckwitzMichael Untch

❮ Previous
Next ❯

Citations

Nov 30, 2013·Breast Cancer Research : BCR·Suzanne A EcclesAlastair M Thompson
Oct 4, 2012·Expert Review of Anticancer Therapy·Mustafa Khasraw, Richard Bell
Apr 24, 2012·Biochimica Et Biophysica Acta·Lian LamHongtao Zhang
Jun 28, 2011·Drug Discovery Today·Radoslaw ZagozdzonJohn Crown
May 10, 2011·Cancer Treatment Reviews·Chantal TséPierre-Jean Lamy
Oct 27, 2010·Annals of the New York Academy of Sciences·Jason A Wilken, Nita J Maihle
Jun 14, 2013·ISRN Oncology·Katarina SevcikovaStanislav Spanik
Feb 22, 2014·Journal of Gastroenterology·Katsunobu OyamaTetsuo Ohta
Jan 27, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chee Khoon LeePaul de Souza
Apr 17, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S SienaL Trusolino
Mar 2, 2018·Laboratory Investigation; a Journal of Technical Methods and Pathology·Alexandre PerrierMathieu Boissan
Aug 2, 2017·Nature Reviews. Clinical Oncology·Isabelle GingrasMartine Piccart-Gebhart
Dec 2, 2017·Clinical Chemistry and Laboratory Medicine : CCLM·Ina Mathilde KjaerJonna Skov Madsen
Feb 20, 2013·Clinical Chemistry and Laboratory Medicine : CCLM·Eva Rabing Brix PetersenIvan Brandslund
Jul 2, 2020·Cancer Management and Research·Pengyu ZhangXuejun Zhang
Jul 7, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sabine RiethdorfKlaus Pantel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.